Both in Biotechnology
Coherus Oncology vs Outlook Therapeutics
Over the past year CHRS returned −49.6% and OTLK returned −64.6%; their daily moves had a correlation of 0.09.
CHRS −49.6% OTLK −64.6%Growth of $1, one year, split-adjusted
| Metric | CHRS | OTLK |
|---|---|---|
| Price | $0.8056 | $0.4600 |
| Market cap | $124.5M | $112.0M |
| Today | +7.50% | −1.96% |
| 1 month | −28.1% | −22.8% |
| 6 months | −55.0% | +90.3% |
| Year to date | −43.3% | −70.9% |
| 1 year | −52.0% | −63.5% |
| Revenue growth (YoY) | +39.5% | −99.4% |
| Gross margin | 70.4% | −95.0% |
| Net margin | −144.2% | −233554.9% |
| P/E (TTM) | — | — |
| Price / sales | 2.4× | — |
| Net cash | $68.1M | -$7.0M |
| Dividend yield | — | — |
| Volatility (60d) | 94.6% | 89.0% |
| Short % of float | 9.5% | 39.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).